Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kyphoplasty & vertebroplasty cases in Illinois: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (184 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 40 | 2,551 | 30% |
| 2020 | 27 | 2,048 | 33% |
| 2021 | 24 | 2,001 | 37% |
| 2022 | 24 | 1,937 | 42% |
| 2023 | 21 | 1,962 | 45% |
| 2024 | 22 | 1,781 | 47% |
| 2025 from claims | – | 1,802 1,654–1,907 | 48% |
| 2026 forecast | – | 1,826 1,607–2,107 | 48% |
| 2027 forecast | – | 1,835 1,568–2,186 | 48% |
| 2028 forecast | – | 1,843 1,538–2,257 | 49% |
| 2029 forecast | – | 1,851 1,512–2,321 | 50% |
| 2030 forecast | – | 1,859 1,489–2,382 | 50% |
Vertebral compression fracture augmentation; IR, pain, spine surgeons. Professional codes (what the surgeon bills): CPT 22513, 22514, 22510, 22511.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 66% of the cases CMS names in Illinois; 15 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 41% inpatient hospital, 43% hospital outpatient, 2% surgery center, 14% office. The share outside the hospital has moved −4 pts since 2019.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 15 | 1,537−7.3%/yr | −7.3%/yr | 1.4 | 1% | 1,360 in 2030−2.1%/yr |
| Missouri | 13 | 1,235−7.5%/yr | −7.5%/yr | 2.0 | 5% | 1,060 in 2030−2.5%/yr |
| Michigan | 11 | 1,216−8.7%/yr | −8.7%/yr | 1.4 | 12% | 1,000 in 2030−3.2%/yr |
| Indiana | 13 | 1,180−9.3%/yr | −9.3%/yr | 1.6 | 19% | 1,300 in 2030+1.7%/yr |
| Kansas | 15 | 1,030−5.7%/yr | −5.7%/yr | 2.5 | 11% | 920 in 2030−1.8%/yr |
| Wisconsin | 5 | 577−4.4%/yr | −4.4%/yr | 1.0 | 12% | 650 in 2030+2%/yr |
| Nebraska | 6 | 473−8.9%/yr | −8.9%/yr | 1.8 | 16% | 510 in 2030+1.3%/yr |
| Minnesota | 1 | 310−5.8%/yr | −5.8%/yr | 0.7 | 8% | 290 in 2030−1.1%/yr |
| Iowa | 2 | 213−11%/yr | −11%/yr | 0.5 | 0% | 130 in 2030−7.9%/yr |
| North Dakota | 4 | 184+3.2%/yr | +3.2%/yr | 1.8 | 0% | 210 in 2030+2.6%/yr |
| South Dakota | 1 | 100−11%/yr | −11%/yr | 0.8 | 0% | 110 in 2030+1.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 81 | 3,603−6.4%/yr | −6.4%/yr | 2.50.8× | 7% | 3,990 in 2030+1.7%/yr |
| Lumbar fusion | 71 | 3,069−2%/yr | −2%/yr | 2.20.8× | 1% | 3,410 in 2030+1.8%/yr |
| Cervical fusion & disc arthroplasty | 28 | 1,515−7.1%/yr | −7.1%/yr | 1.10.8× | 2% | 1,670 in 2030+1.6%/yr |
| SI joint fusion | 2 | 171+8.4%/yr | +8.4%/yr | 0.10.5× | 0% | 380 in 2030+14%/yr |
Kyphoplasty & vertebroplasty in every state, and its device makers · Every procedure market in Illinois · Every state · Compare with Ohio
VB Spine leads with 61% of company spending on these surgeons in 2025, −27 pts on 2024.
In 2025, 4 companies reported engagement with Illinois’s surgeons worth $37K in consulting, speaking, meals and travel tied to these products, about $1,693 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 1 clearance or approval in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.